Cargando…
The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry
BACKGROUND: Using immunohistochemistry (IHC) to select cases for mismatch repair (MMR) genetic testing, we failed to identify a large kindred with the deleterious PMS2 mutation c.989-1G > T. The purpose of the study was to examine the sensitivity of IHC and microsatellite instability-analysis (MS...
Autores principales: | Grindedal, Eli Marie, Aarset, Harald, Bjørnevoll, Inga, Røyset, Elin, Mæhle, Lovise, Stormorken, Astrid, Heramb, Cecilie, Medvik, Heidi, Møller, Pål, Sjursen, Wenche |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005455/ https://www.ncbi.nlm.nih.gov/pubmed/24790682 http://dx.doi.org/10.1186/1897-4287-12-12 |
Ejemplares similares
-
Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers
por: Sjursen, Wenche, et al.
Publicado: (2010) -
Ten modifiers of BRCA1 penetrance validated in a Norwegian series
por: Heramb, Cecilie, et al.
Publicado: (2015) -
“It was an important part of my treatment”: a qualitative study of Norwegian breast Cancer patients’ experiences with mainstreamed genetic testing
por: Strømsvik, Nina, et al.
Publicado: (2022) -
BRCA1 and BRCA2 mutation spectrum – an update on mutation distribution in a large cancer genetics clinic in Norway
por: Heramb, Cecilie, et al.
Publicado: (2018) -
BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
por: Norum, Jan, et al.
Publicado: (2018)